Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof

A method for controlling decomposition of hyaluronic acid, wherein the method comprises applying, to a subject in need thereof, the following i), ii) or iii), for improvement of joint functions, restoration of tissue, amelioration of skin roughness or dry skin, or reduction of wrinkles,

• i) an anti-sense nucleic acid or an siRNA against a KIAA1199 gene;
• ii) an antibody specific to a protein encoded by the KIAA1199 gene;
• or
• iii) a low-molecule compound selected from the group consisting of chlorpromazine, N-ethylmaleimide, bafilomycin A1, monensin, EDTA, deferoxamine, and orientin.

A method for controlling decomposition of hyaluronic acid, wherein the method comprises applying to a subject in need thereof, the following i), ii) or iii):

• for tuning of tissue restoration by hyaluronic acid,
• i) a KIAA1199 gene;
• ii) a protein encoded by the KIAA1199 gene;
• or
• iii) a substance which can promote the expression or activity of the KIAA1199 gene or the protein encoded by the KIAA1199 gene.

A topical preparation comprising hyaluronic acid or a pharmacologically acceptable salt or a derivative thereof, and the following i), ii) or iii):

• i) an anti-sense nucleic acid or an siRNA against a KIAA1199 gene;
• ii) an antibody specific to a protein encoded by the KIAA1199 gene;
• or
• iii) a low-molecule compound selected from the group consisting of chlorpromazine, N-ethylmaleimide, bafilomycin A1, monensin, EDTA, deferoxamine, and orientin.

A hyaluronic acid decomposition controlling effect assessing kit, comprising at least one of the following (a) to (d):

• (a) cells in which a KIAA1199 gene is highly expressed transiently or stably;
• (b) a monoclonal antibody specific to a protein encoded by the KIAA1199 gene;
• (c) an oligonucleotide primer for specifically amplifying the KIAA1199 gene;
• and
• (d) a polynucleotide probe for detecting the KIAA1199 gene by binding specifically to the gene.